BRANFORD, Conn. / Oct 31, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Company will host an Investor & Analyst event in New York City on November 20th, 2024.
Quantum-Si’s management team will provide updates on the Company’s evolving technology roadmap, emerging applications for protein sequencing and the expanding commercial opportunities that these innovations create.
A live question and answer session will follow the formal presentations.
EVENT DETAILS:
WHEN: Wednesday, November 20, 2024 | 10AM – 12PM EST
WHERE: Westin NY Times Square, 270 West 43rd Street, New York, NY, 10036
REGISTRATION LINK (both in-person & virtual*): QSI Investor Day 2024
*In-person attendance is limited to invited research analysts and institutional investors only. All other guests are invited to view the live or archived webcast virtually on the Investor Relations section of Quantum-Si’s website at https://ir.quantum-si.com/. The archived webcast will be available for at least 90 days following the event.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
| Last Trade: | US$1.99 |
| Daily Change: | 0.09 4.74 |
| Daily Volume: | 5,606,179 |
| Market Cap: | US$275.420M |
June 17, 2025 June 10, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
